Variational AI is pleased to share that Rakovina Therapeutics and Variational AI have expanded our collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors, strengthening our joint commitment to accelerating oncology drug discovery through practical, design-first… Read More
Tony Hunter, Ph.D., celebrated for pioneering discoveries that inspired the development of more than 80 cancer therapies that continue to transform patient lives. New Brunswick, N.J. – Johnson & Johnson announced… Read More
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1. At lower doses, patients… Read More
This $2.18-billion hospital — which is designed for the latest and future technologies — is described as the first of its kind in Canada. Vancouver was a rough-and-tumble but burgeoning… Read More
The investment will expand RNA Technologies & Therapeutics’ operations and allow partners of both companies to leverage combined expertise in RNA-LNP therapeutics. Vancouver, BC – Acuitas Therapeutics, the global leader… Read More
